CO6680652A2 - Usos terapéuticos de 1-[2-(2.4-dimetil-fenilsulfanil)fenil]piperazina - Google Patents

Usos terapéuticos de 1-[2-(2.4-dimetil-fenilsulfanil)fenil]piperazina

Info

Publication number
CO6680652A2
CO6680652A2 CO13035030A CO13035030A CO6680652A2 CO 6680652 A2 CO6680652 A2 CO 6680652A2 CO 13035030 A CO13035030 A CO 13035030A CO 13035030 A CO13035030 A CO 13035030A CO 6680652 A2 CO6680652 A2 CO 6680652A2
Authority
CO
Colombia
Prior art keywords
phenylsulfanyl
piperazine
dimethyl
phenyl
therapeutic uses
Prior art date
Application number
CO13035030A
Other languages
English (en)
Inventor
Marianne Dragheim
Ioana Florea
Original Assignee
H Lundbeck & Co As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44532506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6680652(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck & Co As filed Critical H Lundbeck & Co As
Publication of CO6680652A2 publication Critical patent/CO6680652A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1-[2-(2,4-dimetíl-fenilsulfanil) fenil]piperazina y sus sales farmacéuticamente aceptables para el tratamiento de una enfermedad del SNC.
CO13035030A 2010-08-23 2013-02-21 Usos terapéuticos de 1-[2-(2.4-dimetil-fenilsulfanil)fenil]piperazina CO6680652A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201000739 2010-08-23

Publications (1)

Publication Number Publication Date
CO6680652A2 true CO6680652A2 (es) 2013-05-31

Family

ID=44532506

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13035030A CO6680652A2 (es) 2010-08-23 2013-02-21 Usos terapéuticos de 1-[2-(2.4-dimetil-fenilsulfanil)fenil]piperazina

Country Status (30)

Country Link
US (5) US20130184291A1 (es)
EP (1) EP2608789B2 (es)
JP (1) JP5902169B2 (es)
KR (1) KR101816953B1 (es)
CN (1) CN103068389A (es)
AP (1) AP3583A (es)
AR (1) AR082501A1 (es)
AU (1) AU2011295465B8 (es)
BR (2) BR112013002194A2 (es)
CA (1) CA2807062C (es)
CL (1) CL2013000492A1 (es)
CO (1) CO6680652A2 (es)
CY (1) CY1118886T1 (es)
DK (1) DK2608789T3 (es)
ES (1) ES2625142T3 (es)
HR (1) HRP20170608T1 (es)
HU (1) HUE034155T2 (es)
IL (1) IL224371A (es)
LT (1) LT2608789T (es)
ME (1) ME02674B (es)
MX (1) MX349724B (es)
PL (1) PL2608789T3 (es)
PT (1) PT2608789T (es)
RS (1) RS55851B1 (es)
RU (1) RU2564666C2 (es)
SG (1) SG187649A1 (es)
SI (1) SI2608789T1 (es)
TW (1) TW201212918A (es)
WO (1) WO2012025123A1 (es)
ZA (1) ZA201301385B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9822086B2 (en) 2014-01-31 2017-11-21 Egis Gyogyszergyar Zrt. Process for the preparation of vortioxetine salts
CN104119298B (zh) * 2014-08-13 2016-08-24 北京蓝贝望生物医药科技股份有限公司 氢溴酸沃赛汀或氢溴酸沃替西汀
CN104119299B (zh) * 2014-08-13 2016-08-17 北京蓝贝望生物医药科技股份有限公司 沃赛汀或沃替西汀的氢溴酸盐
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
KR20190025556A (ko) 2016-07-01 2019-03-11 하. 룬드벡 아크티에셀스카브 항우울 효과의 신속한 개시를 위한 보티옥세틴 투여 요법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
EP0543584B1 (en) * 1991-11-18 1996-05-22 Lilly Industries Limited Benzo(b)thiophene-2-carboxamides for the treatment of disorders of the central nervous system
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7159383B2 (en) 2000-10-02 2007-01-09 Rohr, Inc. Apparatus, method and system for gas turbine engine noise reduction
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
BR122020011899B1 (pt) * 2006-06-16 2021-05-11 H. Lundbeck A/S processos para a preparação de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]-piperazina e para a fabricação do sal de adição de ácido bromídrico correspondente
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity

Also Published As

Publication number Publication date
US20130184291A1 (en) 2013-07-18
AP3583A (en) 2016-02-09
PT2608789T (pt) 2017-05-26
IL224371A (en) 2016-07-31
US20220370439A1 (en) 2022-11-24
RS55851B1 (sr) 2017-08-31
BR122020025600A2 (pt) 2021-01-05
KR20130097162A (ko) 2013-09-02
SG187649A1 (en) 2013-03-28
BR112013002194A2 (pt) 2016-05-31
CL2013000492A1 (es) 2013-06-07
AR082501A1 (es) 2012-12-12
JP5902169B2 (ja) 2016-04-13
ZA201301385B (en) 2014-04-30
CY1118886T1 (el) 2018-01-10
RU2564666C2 (ru) 2015-10-10
EP2608789A1 (en) 2013-07-03
CN103068389A (zh) 2013-04-24
ES2625142T3 (es) 2017-07-18
US20210085674A1 (en) 2021-03-25
KR101816953B1 (ko) 2018-01-09
CA2807062C (en) 2018-07-31
CA2807062A1 (en) 2012-03-01
JP2013536206A (ja) 2013-09-19
AP2013006768A0 (en) 2012-03-31
MX349724B (es) 2017-08-10
US20190000836A1 (en) 2019-01-03
DK2608789T3 (en) 2017-05-15
TW201212918A (en) 2012-04-01
AU2011295465B2 (en) 2014-06-19
AU2011295465B8 (en) 2014-07-10
SI2608789T1 (sl) 2017-06-30
ME02674B (me) 2017-06-20
EP2608789B2 (en) 2024-08-21
WO2012025123A1 (en) 2012-03-01
EP2608789B1 (en) 2017-04-12
RU2013112890A (ru) 2014-09-27
US20240293397A1 (en) 2024-09-05
PL2608789T3 (pl) 2017-09-29
MX2013001570A (es) 2013-03-21
HUE034155T2 (en) 2018-01-29
LT2608789T (lt) 2017-05-25
HRP20170608T1 (hr) 2017-07-28
AU2011295465A1 (en) 2013-02-07

Similar Documents

Publication Publication Date Title
AR122051A2 (es) Formulaciones líquidas de sales de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina
CO6480932A2 (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida.
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CR20130629A (es) Compuestos de 2-(2,4,5-anilino sustituido)pirimidina
ECSP14013199A (es) Compuestos para el tratamiento y profilaxis de la enfermedad del virus sincicial respiratorio
CR20130377A (es) Métodos y productos de fármaco para tratar enfermedad de alzheimer
CR20120316A (es) Procesos para la fabricación de un agente farmacéuticamente activo
UY34775A (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis múltiple
EA201790627A1 (ru) СТИМУЛЯТОРЫ рГЦ
CO6680652A2 (es) Usos terapéuticos de 1-[2-(2.4-dimetil-fenilsulfanil)fenil]piperazina
CU20160140A7 (es) CROMENE Y 1,1 A,2,7B- tetrahidrociclopropa[C]CROMENE PIRIDOPIRAZINEDIONES COMO MODULADORES DE GAMMA-SECRETASA
DOP2012000058A (es) Agente terapeutico para trastornos del estado de animo
DOP2012000050A (es) Nuevas composiciones de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil] piperazina
UY34786A (es) Procedimiento para la fabricación de una forma farmacéutica que comprende nifedipino y candesartan cilexetilo
CL2017001467A1 (es) Compuestos de dihidropirimidin - 2 - ona y sus usos médicos
SV2016005313A (es) Derivados de carboxamida
ECSP19019613A (es) Compuestos de aza–indazol para usar en lesiones de tendones y/o ligamentos
CR11759A (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
EA033423B1 (ru) Циклопропанбензофуранилпиридопиразиндионы
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
DOP2010000327A (es) Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento de nivel de creatinina debido a la administracion de dronedarona
ECSP16086217A (es) Proceso para obtener enantiómeros de pirlindole opticamente activos y sales del mismo
MA39450A1 (fr) Sels pharmaceutiquement acceptables d'énantiomères de pirlindole s'utilisant en médecine
DOP2012000056A (es) Agente terapeutico para trastornos de ansiedad
UY34320A (es) 2-(croman-6-iloxi)-tiazoles sustituidos y su uso como productos farmacéuticos.